Monoclonal antibody therapy of chronic lymphocytic leukaemia

Best Practice & Research. Clinical Haematology
Bruce D Cheson

Abstract

The availability of safe and effective monoclonal antibodies has revolutionised the treatment strategies for patients with chronic lymphocytic leukaemia (CLL). Alemtuzumab, the first antibody approved for these patients, induces responses in one-third of relapsed and refractory patients, and in more than 80% when used as initial therapy. Rituximab, while exhibiting modest single-agent activity, improves the response rate when added to standard chemotherapy and may even prolong patient survival. The most recent antibody to be approved by regulatory agencies is ofatumumab, a new anti-CD20 antibody, with efficacy in patients whose disease is refractory to both fludarabine and alemtuzumab. Other antibodies or related molecules in development are directed at antigens, such as CD20, CD23 and CD37. Through rational combinations with chemotherapy and other biologic agents, the outcome for patients with CLL will further improve.

References

Mar 1, 1990·Tissue Antigens·G HaleH Waldmann
Jan 1, 1981·The Journal of Clinical Investigation·L M NadlerP Stashenko
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthUNKNOWN Minnie Pearl Cancer Research Network
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul MoretonPeter Hillmen
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William WierdaMichael Keating
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnMartin S Tallman
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan StilgenbauerUNKNOWN German Chronic Lymphocytic Leukemia Study Group
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tadeusz RobakSergey I Moiseev

❮ Previous
Next ❯

Citations

Sep 16, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaowen GeXuebin Qin
Mar 5, 2011·Fluids and Barriers of the CNS·Cody L WestonJames R Connor
Jul 23, 2013·Blood Reviews·Anna MartnerKristoffer Hellstrand
Oct 26, 2011·Leukemia & Lymphoma·Pauline Y HuangRichard I Christopherson
Nov 15, 2015·Expert Opinion on Drug Safety·Anna Korycka-WołowiecTadeusz Robak
Jul 15, 2015·Expert Opinion on Drug Metabolism & Toxicology·Anna Korycka-WołowiecTadeusz Robak
Jul 18, 2015·The Annals of Pharmacotherapy·Arpita Shah, Abhishek Mangaonkar
Nov 24, 2016·Expert Opinion on Drug Safety·Anna Korycka-WołowiecTadeusz Robak
Apr 18, 2019·Autism : the International Journal of Research and Practice·Hannah Legg, Anna Tickle
Dec 7, 2011·Cancer Control : Journal of the Moffitt Cancer Center·Marays Veliz, Javier Pinilla-Ibarz
Aug 10, 2012·Cancer Research·Karrie K WongReginald M Gorczynski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.